The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
|Articles|April 21, 2023
Earth Day 2023: Climate Change and Infectious Disease
Author(s)Nina Cosdon
The floods, heat waves, droughts, and other calamities caused by excessive greenhouse gas emissions also make us more vulnerable to ill effects of pathogens such as bacteria, viruses, plants and fungi.
Advertisement
Every April 22, we celebrate Earth Day to demonstrate environmental protection and reflect on its importance.
As the planet has heated up in recent years, so have disease outbreaks. This Earth Day 2023, we're sharing 5 recent stories that shed light on the linkage between climate change and infectious disease.
Advertisement
Related to this article
Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
FDA-cleared single-step immunoblot tests built on recombinant antigens from multiple Borrelia species detected nearly twice as many early Lyme disease cases as standard 2-tier testing. Joseph J. Burrascano Jr, MD, offers insights into what the new tests mean for clinicians.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Advertisement
Advertisement